Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation.

[1]  M. Lulli,et al.  CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression , 2017, Gut.

[2]  G. Marchesini,et al.  Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease , 2017, Alimentary pharmacology & therapeutics.

[3]  Manuela Merli,et al.  Sarcopenia from mechanism to diagnosis and treatment in liver disease. , 2016, Journal of hepatology.

[4]  A. Gentilini,et al.  Molecular Pathogenesis of NASH , 2016, International journal of molecular sciences.

[5]  C. Tripodo,et al.  MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[6]  Aijaz Ahmed,et al.  Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  R. Kambadur,et al.  Myostatin: Expanding horizons , 2015, IUBMB life.

[8]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[9]  S. Friedman,et al.  Emerging and Disease-Specific Mechanisms of Hepatic Stellate Cell Activation , 2015, Seminars in Liver Disease.

[10]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[11]  C. Trautwein,et al.  Hepatic fibrosis: Concept to treatment. , 2015, Journal of hepatology.

[12]  T. Borchardt,et al.  Myostatin induces interstitial fibrosis in the heart via TAK1 and p38 , 2015, Cell and Tissue Research.

[13]  S. Friedman,et al.  IL-17A Enhances the Expression of Profibrotic Genes through Upregulation of the TGF-β Receptor on Hepatic Stellate Cells in a JNK-Dependent Manner , 2014, The Journal of Immunology.

[14]  N. Gray,et al.  The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma , 2014, Gut.

[15]  S. Lotersztajn,et al.  The metabolic syndrome and chronic liver disease. , 2014, Current pharmaceutical design.

[16]  C. Reutelingsperger,et al.  Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice , 2014, Hepatology.

[17]  G. Svegliati-Baroni,et al.  Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice , 2014, Hepatology.

[18]  R. Schwabe,et al.  Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.

[19]  Jiangyang Zhang,et al.  Inhibition of myostatin reverses muscle fibrosis through apoptosis , 2012, Journal of Cell Science.

[20]  D. Glass,et al.  Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.

[21]  Michael Karin,et al.  A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. , 2012, Gastroenterology.

[22]  N. Tan,et al.  Myostatin-null mice exhibit delayed skin wound healing through the blockade of transforming growth factor-β signaling by decorin. , 2012, American journal of physiology. Cell physiology.

[23]  F. Marra,et al.  The biphasic nature of hypoxia‐induced directional migration of activated human hepatic stellate cells , 2012, The Journal of pathology.

[24]  Daiwen Chen,et al.  Myostatin: a novel insight into its role in metabolism, signal pathways, and expression regulation. , 2011, Cellular signalling.

[25]  J. Ketelslegers,et al.  Increased plasma myostatin in heart failure , 2011, European journal of heart failure.

[26]  G. Shulman,et al.  The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. , 2010, Annual review of nutrition.

[27]  S. Milani,et al.  Curcumin limits the fibrogenic evolution of experimental steatohepatitis , 2010, Laboratory Investigation.

[28]  F. Marra,et al.  Adipokines in liver diseases , 2009, Hepatology.

[29]  A. Vaag,et al.  Gene Expression in Skeletal Muscle Biopsies from People with Type 2 Diabetes and Relatives: Differential Regulation of Insulin Signaling Pathways , 2009, PloS one.

[30]  N. Gekakis,et al.  Loss-of-Function Mutation in Myostatin Reduces Tumor Necrosis Factor α Production and Protects Liver Against Obesity-Induced Insulin Resistance , 2009, Diabetes.

[31]  K. Wagner,et al.  Myostatin Directly Regulates Skeletal Muscle Fibrosis* , 2008, Journal of Biological Chemistry.

[32]  M. Ferrini,et al.  Profibrotic role of myostatin in Peyronie's disease. , 2008, The journal of sexual medicine.

[33]  S. Krämer,et al.  Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis , 2008, Molecular and Cellular Biochemistry.

[34]  S. Gelmini,et al.  Adenosine monophosphate–activated protein kinase modulates the activated phenotype of hepatic stellate cells , 2007, Hepatology.

[35]  S. Friedman.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. , 2008, Physiological reviews.

[36]  Daiwen Chen,et al.  Regulation of myostatin signaling by c-Jun N-terminal kinase in C2C12 cells. , 2007, Cellular signalling.

[37]  F. Ambrosio,et al.  Relationships between transforming growth factor-beta1, myostatin, and decorin: implications for skeletal muscle fibrosis. , 2007, The Journal of biological chemistry.

[38]  G. Mingrone,et al.  Changes in muscle myostatin expression in obese subjects after weight loss. , 2004, The Journal of clinical endocrinology and metabolism.

[39]  Se-Jin Lee,et al.  Suppression of body fat accumulation in myostatin-deficient mice. , 2002, The Journal of clinical investigation.

[40]  Se-Jin Lee,et al.  Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.

[41]  H. Herbst,et al.  Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. , 1997, Gastroenterology.